Orum: Orum is an AI-powered platform designed to enhance sales activities, streamline team connections, and boost revenue. It facilitates live conversations to supercharge business operations.
Thnks: Thanks, the system operates by processing user inputs and generating relevant responses. Queries are analyzed, and appropriate answers are formulated accordingly.
Introducing Orum and Thnks
Orum belong to a category of solutions that help Auto Dialer, whereas Thnks belong to a category of solutions that help Marketing Automation. Different products excel in different areas, so the best platform for your business will depend on your specific needs and requirements.
Orum covers Telemarketing with Phone Calls, Workflow Management with Phone Calls, Contact List Management with Phone Calls, Communication Management.
Thnks focuses on Social Media Management, Engagement Management, Communication Management, Customer Feedback Management, etc.
Unsure which of these solutions is right for you? Our Cuspera AI engine can compare them based on your needs and specific to your industry and context. Get your personalized report today.
Orum and Thnks: Best activities based on customer satisfaction
Top Processes
Customer evidence for the processes each product supports. Click Read Reviews to open peer feedback.
Evidences indicate better relative satisfaction
Top Goals
Goals Achieved
-
Acquire customers
-
Enhance customer relationships
-
Increase sales & revenue
-
Build brand awareness
- See 1 more
IT and Other Capabilities
- Low
- Medium
- High
Data
Support
Others
Business Setting
| Orum | Thnks | |
|---|---|---|
| Peer score | 3.9 | 4.0 |
| Peer insights | 18 | 104 |
| Top industries |
Computer Software 52.0%
Information Technology And Services 48.0%
|
|
| SMB and Mid-Market | 100.0% | 0.0% |
| Enterprise | 0.0% | 0.0% |
News
Latest Orum news
BrisÂtol MyÂers scraps $100M Orum canÂcer drug afÂter reÂviewÂing Phase 1 daÂta
Bristol Myers Squibb has terminated the development of a cancer drug, BMS-986497/ORM-6151, which was co-developed with Orum, following a review of Phase 1 data.